Antileishmanial effects of clofazimine and other antimycobacterial agents

REFERENCES

• Aguillar, C. M., Fernandez, E., Fernandez de, R. & Deane, L. M. (1984). Study of an outbreak of cutaneous leishmaniasis in Venezuela. The role of domestic animals. Memorias do Instituto Oswaldo Cruz, 79, 181–195.
   PubMedGoogle Scholar
• Anderson, R. (1985). Enhancement by clofazimine and inhibition by dapsone of production of prostaglandin E by human polymorphonuclear leukocytes in vitro. Antimicrobial Agents and Chemotherapy, 27, 257–262.
   PubMed Web of Science ®Google Scholar
• Banerjee, D. K., Ellard, G. A. & Gammon, T. (1974). Some observations on the pharmacology of clofazimine. American Journal of Tropical Medicine and Hygiene, 23, 1110–1115.
   PubMed Web of Science ®Google Scholar
• Berghem, L., Lahnborg, G. & Schildt, B. (1977). Does clofazimine affect the micro- and macrophage function in man. Journal of the Reticuloendothelial Society (U.S.A.), 21, 171–173.
   Google Scholar
• Borst, P. & Fairlamb, A. H. (1976). DNA of parasites, with special reference to kinetoplast DNA. In Biochemistry of Parasites and Host-Parasite Relationships, ed. Van den Bossche, H., pp. 169–192. Amsterdam, North Holland: Elsevier.
   Google Scholar
• Bygbjerg, I. C., Knudsen, L. & Kieffer, M. (1980). Failure of rifampicin therapy to cure cutaneous leishmaniasis. Archives of Dermatology, 116, 998.
   Google Scholar
• Casile, M. & Saccharin, H. (1953). On the treatment of American leishmaniasis. Bulletin de la Société de Pathologie Exotique,46, 184–188.
   Google Scholar
• Clive, M. J. (1970). Drug potentiation of macrophage function. Infection and Immunity, 2, 601–605.
   PubMedGoogle Scholar
• Desikan, K. V. & Balakrishnan, S. (1976). Tissue levels of clofazimine in a case of leprosy. Leprosy Reviews, 47, 107–113.
   PubMedGoogle Scholar
• Durado, K. V., Borborema, C. T., Alegrin, W. & Tahai, S. (1975). American cutaneous leishmaniasis: treatment with rifampicin. Revista Brasiliera Clinica et Terepeutica, 4, 1–6.
   Google Scholar
• Ellis, B. P. B. & Taube, E. (1973). Clofazimine ointment in the treatment of trophic ulcers. South African Medical Journal, 47, 378–379.
   PubMed Web of Science ®Google Scholar
• El-On, J. & Greenblatt, C. L. (1983). An in vitro model for testing possible effects of antileishmanial drugs of possible use in topical treatment. Current Therapeutic Research, 33, 660–669.
   Web of Science ®Google Scholar
• El-On, J., Messer, G. & Greenblatt, C. L. (1984a). Growth inhibition of L. tropica amastigotes in vitro by rifampicin combined with amphotericin B. Annals of Tropical Medicine and Parasitology, 78, 93–98.
   PubMed Web of Science ®Google Scholar
• El-On, J., Jacobs, G. P., Witzum, E. & Greenblatt, C. L. (1984b). Development of topical treatment for cutaneous leishmaniasis caused by L. major in experimental animals. Antimicrobial Agents and Chemotherapy, 26, 745–751.
   PubMed Web of Science ®Google Scholar
• Evans, D. A. (1978). Kinetoplastida. In Methods of Cultivating Parasites In Vitro, eds. Taylor, A. E. R. & Baker, J. R., pp. 55–88. London: Academic Press.
   Google Scholar
• Even-Paz, Z., Weinrauch, L., Lillshina, R., El-On, J. & Greenblatt, C. L. (1982). Rifampicin treatment of cutaneous disease. International Journal of Dermatology, 21, 110–112.
   PubMed Web of Science ®Google Scholar
• Griffiths, W. A. D. & Sodeify, M. (1976). Use of metronidazole in cutaneous leishmaniasis. Archives of Dermatology, 112, 1791.
   PubMedGoogle Scholar
• Iskander, I. O. (1978). Rifampicin in cutaneous leishmaniasis. Journal of International Medical Research, 6, 280–285.
   PubMed Web of Science ®Google Scholar
• Keithly, J. S. & Langreth, S. G. (1983). Inefficacy of metronidazole in experimental infections of L. donovani, L. mexicana and T. brucei brucei. American Journal of Tropical Medicine and Hygiene, 32, 485–496.
   PubMed Web of Science ®Google Scholar
• Knight, V. In Barry, V. C. & Conalty, M. L. (1965). The antimycobacterial activity ofB663. Leprosy Reviews, 36, 3–8.
   PubMedGoogle Scholar
• Levy, L. (1974). Pharmacologic studies of clofazimine. American Journal of Tropical Medicine and Hygiene, 23, 1097–1109.
   PubMed Web of Science ®Google Scholar
• Lindtjorn, B. (1981). Antituberculous drugs and kala-azar. Lancet, ii, 304.
   Google Scholar
• Morrison, W. E. & Mauley, G. M. (1976). Clofazimine binding studies with deoxyribonucleic acid. International Journal of Leprosy, 44, 475–481.
   Google Scholar
• Murphy, K. J. & Bong, A. W. (1981). Co-trimoxazole for systemic leishmaniasis. Lancet, i, 323–324.
   Google Scholar
• Neal, R. A. (1976). Effect of sodium stibogluconate and pyrimethamine on mouse infections with L. mexicana. Annals of Tropical Medicine and Parasitology, 70, 252.
   PubMed Web of Science ®Google Scholar
• Neal, R. A. & Croft, S. L. (1984). An in vitro system for determining the activity of compounds against the intracellular amastigote form of L. donovani. Journal of Antimicrobial Chemotherapy, 14, 463–475.
   PubMed Web of Science ®Google Scholar
• Peters, W., Lainson, R., Shaw, J. J., Robinson, B. L. & Franca-Leao, A. (1981). Potentiating action of rifampicin and isoniazid against L. mexicana amazonensis. Lancet, i, 1122–1123.
   Google Scholar
• Rotta, O., Mota, R. M. & Cuce, L. C. (1975). Tratamento da Leishmaniose tegumentar Americana com clofazimina. Anais Brasilieros de Dermatologica, 50, 197–201.
   Google Scholar
• Sarracent, J. & Finlay, A. M. (1982a). The action of clofazimine at the level of lysosomal enzymes of cultured macrophages. Clinical and Experimental Immunology, 18, 261–267.
   Google Scholar
• Sarracent, J. & Finlay, C. M. (1982b). Phagocytosis and intracellular degradation of l25 I-labelled immune complexes by clofazimine-treated macrophage cultures. Clinical and Experimental Immunology, 48, 268–272.
   PubMed Web of Science ®Google Scholar
• Schattenkerk, J. K. M., Bhatt, S. M. & Rees, P. H. (1981). Antituberculous drugs and kala-azar. Lancet, ii, 304.
   Google Scholar
• Selim, M. M. & Kandil, E. (1972). Rifampicin in the treatment of cutaneous leishmaniasis. Journal of the Kuwait Medical Association, 6, 159–166.
   Google Scholar
• Trotter, E. R., Peters, W. & Robinson, B. L. (1980a). The experimental chemotherapy of leishmaniasis IV: the development of a rodent model for visceral infection. Annals of Tropical Medicine and Parasitology, 74, 127–138.
   PubMed Web of Science ®Google Scholar
• Trotter, E. R., Peters, W. & Robinson, B. L. (1980b). The experimental chemotherapy of leishmaniasis VI: the development of rodent models for cutaneous infection with L. major and L. m. amazonensis. Annals of Tropical Medicine and Parasitology, 74, 299–319.
   PubMed Web of Science ®Google Scholar
• Van der Meulen, J., Mock, B., Fekete, R. & Sarojini, P. A. (1981). Limited therapeutic action of rifampicin/ isoniazid against Leishmania aethiopica. Lancet, ii, 197–198.
   Google Scholar
• Vasquez, F. R. (1977). Rifampicin in leishmaniasis. Archives of Dermatology, 113, 1610–1611.
   PubMedGoogle Scholar
• White, S. W., Hendricks, L. D. & Chulay, J. D. (1980). Leishmaniasis: a case history and treatment failure with rifampicin. Archives of Dermatology, 116, 620.
   PubMedGoogle Scholar
• Yawalker, S. J. & Vischer, W. (1979). Lamprene (clofazimine) in leprosy. Leprosy Reviews, 50, 135–144.
   PubMed Web of Science ®Google Scholar